These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 25013914)

  • 21. MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints.
    Wei J; Nduom EK; Kong LY; Hashimoto Y; Xu S; Gabrusiewicz K; Ling X; Huang N; Qiao W; Zhou S; Ivan C; Fuller GN; Gilbert MR; Overwijk W; Calin GA; Heimberger AB
    Neuro Oncol; 2016 May; 18(5):639-48. PubMed ID: 26658052
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.
    Reardon DA; Gokhale PC; Klein SR; Ligon KL; Rodig SJ; Ramkissoon SH; Jones KL; Conway AS; Liao X; Zhou J; Wen PY; Van Den Abbeele AD; Hodi FS; Qin L; Kohl NE; Sharpe AH; Dranoff G; Freeman GJ
    Cancer Immunol Res; 2016 Feb; 4(2):124-35. PubMed ID: 26546453
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma.
    Wu L; Yun Z; Tagawa T; Rey-McIntyre K; de Perrot M
    Mol Cancer Ther; 2012 Aug; 11(8):1809-19. PubMed ID: 22584123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function.
    Wen T; Bukczynski J; Watts TH
    J Immunol; 2002 May; 168(10):4897-906. PubMed ID: 11994439
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade.
    Saha D; Martuza RL; Rabkin SD
    Cancer Cell; 2017 Aug; 32(2):253-267.e5. PubMed ID: 28810147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
    Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
    Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases.
    Pan PY; Zang Y; Weber K; Meseck ML; Chen SH
    Mol Ther; 2002 Oct; 6(4):528-36. PubMed ID: 12377195
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
    Kawano M; Itonaga I; Iwasaki T; Tsumura H
    Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice.
    Mahvi DA; Meyers JV; Tatar AJ; Contreras A; Suresh M; Leverson GE; Sen S; Cho CS
    J Immunother; 2015; 38(2):54-61. PubMed ID: 25658614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.
    Zeng J; See AP; Phallen J; Jackson CM; Belcaid Z; Ruzevick J; Durham N; Meyer C; Harris TJ; Albesiano E; Pradilla G; Ford E; Wong J; Hammers HJ; Mathios D; Tyler B; Brem H; Tran PT; Pardoll D; Drake CG; Lim M
    Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):343-9. PubMed ID: 23462419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EZH2 Inhibition Compromises α4-1BB-Mediated Antitumor Efficacy by Reducing the Survival and Effector Programming of CD8
    Stairiker CJ; Pfister SX; Hendrickson E; Yang W; Xie T; Lee C; Zhang H; Dillon C; Thomas GD; Salek-Ardakani S
    Front Immunol; 2021; 12():770080. PubMed ID: 34925340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.
    Linch SN; Kasiewicz MJ; McNamara MJ; Hilgart-Martiszus IF; Farhad M; Redmond WL
    Proc Natl Acad Sci U S A; 2016 Jan; 113(3):E319-27. PubMed ID: 26729864
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination immunotherapy with 4-1BBL and CTLA-4 blockade for the treatment of prostate cancer.
    Youlin K; Li Z; Xiaodong W; Xiuheng L; Hengchen Z
    Clin Dev Immunol; 2012; 2012():439235. PubMed ID: 22312406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models.
    Puigdelloses M; Garcia-Moure M; Labiano S; Laspidea V; Gonzalez-Huarriz M; Zalacain M; Marrodan L; Martinez-Velez N; De la Nava D; Ausejo I; Hervás-Stubbs S; Herrador G; Chen Z; Hambardzumyan D; Patino Garcia A; Jiang H; Gomez-Manzano C; Fueyo J; Gállego Pérez-Larraya J; Alonso M
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34281988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytotoxic T lymphocyte antigen-4 blockade enhances antitumor immunity by stimulating melanoma-specific T-cell motility.
    Pentcheva-Hoang T; Simpson TR; Montalvo-Ortiz W; Allison JP
    Cancer Immunol Res; 2014 Oct; 2(10):970-80. PubMed ID: 25038199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
    Simpson TR; Li F; Montalvo-Ortiz W; Sepulveda MA; Bergerhoff K; Arce F; Roddie C; Henry JY; Yagita H; Wolchok JD; Peggs KS; Ravetch JV; Allison JP; Quezada SA
    J Exp Med; 2013 Aug; 210(9):1695-710. PubMed ID: 23897981
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.
    Mangsbo SM; Sandin LC; Anger K; Korman AJ; Loskog A; Tötterman TH
    J Immunother; 2010 Apr; 33(3):225-35. PubMed ID: 20445343
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
    van Elsas A; Hurwitz AA; Allison JP
    J Exp Med; 1999 Aug; 190(3):355-66. PubMed ID: 10430624
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.
    Rausch J; Lopez PA; Bialojan A; Denny M; Langguth P; Probst HC; Schild H; Radsak MP
    J Dermatol Sci; 2017 Sep; 87(3):300-306. PubMed ID: 28666747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner.
    Miller RE; Jones J; Le T; Whitmore J; Boiani N; Gliniak B; Lynch DH
    J Immunol; 2002 Aug; 169(4):1792-800. PubMed ID: 12165501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.